Cited 33 times in
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.